LEADER 01850nam 2200541 450 001 9910826992503321 005 20231212054038.0 010 $a1-119-16490-7 010 $a1-119-16489-3 010 $a1-119-16488-5 035 $a(CKB)4330000000009016 035 $a(MiAaPQ)EBC4800253 035 $a(DLC) 2016054026 035 $a(Au-PeEL)EBL4800253 035 $a(CaPaEBR)ebr11338246 035 $a(CaONFJC)MIL991457 035 $a(OCoLC)964066028 035 $a(EXLCZ)994330000000009016 100 $a20170217h20172017 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aStill moving $ehow to lead mindful change /$fDeborah Rowland 210 1$aChichester, West Sussex, England :$cWiley-Blackwell,$d2017. 210 4$dİ2017 215 $a1 online resource (271 pages) 225 1 $aTHEi Wiley ebooks 311 $a1-119-16492-3 320 $aIncludes bibliographical references and index. 327 $a. introduction -- Is change changing? -- Still moving : the inner and outer skills -- It all starts in mindfulness -- The power of the systemic -- Make disturbance your friend -- Holding the fire -- The time for emergence -- A tale of still moving and business transformation -- Still moving and your leadership -- The sense of an ending. 410 0$aTHEi Wiley ebooks. 606 $aOrganizational change 606 $aLeadership 606 $aMindfulness (Psychology) 615 0$aOrganizational change. 615 0$aLeadership. 615 0$aMindfulness (Psychology) 676 $a658.4/06 700 $aRowland$b Deborah$01615773 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910826992503321 996 $aStill moving$94086866 997 $aUNINA LEADER 04602nam 2201333z- 450 001 9910557607703321 005 20220111 035 $a(CKB)5400000000045325 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77070 035 $a(oapen)doab77070 035 $a(EXLCZ)995400000000045325 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDrug Metabolism/Transport and Pharmacokinetics 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (232 p.) 311 08$a3-0365-2459-2 311 08$a3-0365-2458-4 330 $aThis book serves to highlight the pharmacokinetics/drug-drug interactions and mechanistic understanding in relation to the drug-metabolizing enzymes and drug transporters.This book presents a series of drug metabolism and transport mechanisms that govern the pharmacokinetic features of therapeutic drugs as well as natural herbal medicines. It also covers the pharmacokinetic interactions caused by inhibiting or inducing the metabolic or transport activities under disease states or the coadministration of potential inhibitors. It also deals with microenvironmental pharmacokinetic profiles as well as population pharmacokinetics, which gives new insights regarding the pharmacokinetic features with regard to drug metabolism and transporters. 606 $aManufacturing industries$2bicssc 606 $aMedicine and Nursing$2bicssc 610 $aacute renal failure 610 $aanti-obesity agent 610 $aautomatization 610 $aBCRP 610 $abiliary excretion 610 $abreast cancer resistance protein 610 $aCaco-2 610 $acarboxylesterase 610 $aCarthamus tinctorius extract 610 $acatalposide 610 $acelecoxib 610 $acisplatin 610 $acomparative pharmacokinetic study 610 $acompatibility mechanism 610 $acompound K 610 $acreatinine clearance 610 $aCYP3A4 610 $acytochrome P450 610 $acytochrome P450 enzymes 610 $adiabetes 610 $adose-dependent pharmacokinetics 610 $adrug absorption 610 $adrug dosing 610 $adrug interaction 610 $adrug transporter 610 $adrug-drug interaction 610 $aDWP16001 610 $aefflux transporter 610 $aEpiIntestinal 610 $afirst-pass 610 $afluorescence 610 $afood-drug interactions 610 $agentamicin 610 $ahead-and-neck cancer 610 $ahealthy Korean subjects 610 $ahepatic and intestinal first-pass effect 610 $ahepatic CYP3A1(23) 610 $aHPLC 610 $aHSG4112 610 $ahuman hepatocytes 610 $ain vitro human metabolism 610 $ainflux transporter 610 $ainhibition mode 610 $ainhibitor 610 $aintestinal metabolism 610 $akidney distribution 610 $akinetic analysis 610 $alarge volume direct injection 610 $amertansine 610 $ametabolism 610 $ametformin 610 $amodeling 610 $anonrenal clearance 610 $anotoginseng total saponins 610 $aoral availability 610 $aorganic cation transporter 2 610 $aP-gp 610 $apharmacokinetics 610 $aphysiologically based pharmacokinetic model 610 $apopulation pharmacokinetic 610 $aprazosin 610 $aprotopanaxadiol (PPD) 610 $aquercetin 610 $arats 610 $areal-time measurements 610 $arenal clearance 610 $arenal excretion 610 $arepaglinide 610 $asodium-glucose cotransporter 2 (SGLT2) inhibitors 610 $astereoselectivity 610 $asulfasalazine 610 $asulfotransferase 610 $ataxanes 610 $atiropramide 610 $atissue engineering 610 $atofacitinib 610 $atransporter-enzyme interplay 610 $aUDP-glucuronosyltransferase 610 $aUDP-glucuronosyltransferases 610 $aUHPLC-MS/MS 610 $averapamil 615 7$aManufacturing industries 615 7$aMedicine and Nursing 700 $aSong$b Im-Sook$4edt$01302990 702 $aSong$b Im-Sook$4oth 906 $aBOOK 912 $a9910557607703321 996 $aDrug Metabolism$93038985 997 $aUNINA